



Integra NeuroSciences Features the Integra NPH Low Flow Hydrocephalus Valve at the Congress of Neurological Surgeons Annual Meeting

PLAINSBORO, N.J., Oct. 10, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) is featuring the Integra NPH™ Low Flow Hydrocephalus Valve (Integra NPH™ Valve) this week at the 55th Annual Meeting of the Congress of Neurological Surgeons in Boston. Integra LifeSciences introduced the Integra NPH™ Valve a year ago, and markets and sells the product through its direct Integra NeuroSciences™ sales force. Since its launch, the Integra NPH™ Valve has been positively received by the medical community.

"The Integra NPH Valve has provided a unique solution for my patients suffering from normal pressure hydrocephalus," said John Abrahams MD, Neurosurgeon at Westchester Medical Center in Valhalla, New York. "The Integra NPH Valve offers an alternative to programmable valves that is safe, cost effective and eliminates any MRI concerns. Overdrainage is one of the key complications resulting from shunting NPH patients. In my nine to twelve month follow-up experience with the Integra NPH Valve in over a dozen patients, there have been no incidences of overdrainage. For these reasons, I have made the Integra NPH Valve my shunt of choice in treating patients with normal pressure hydrocephalus."

The Integra NPH Valve is part of an implantable system used in the treatment of normal pressure hydrocephalus (NPH). The system shunts cerebrospinal fluid (CSF) from the ventricles of the brain to an appropriate drainage site, such as the peritoneal cavity or the heart's right atrium. Designed specifically to meet the needs of patients with NPH, the Integra NPH Valve controls CSF flow at a lower rate than Integra's other flow-control valves. With three stages of operation, the Integra NPH Valve acts as a conventional differential pressure valve, maintains CSF flow rate within a specified range, and, in the event of sudden increases in intraventricular pressure, operates in a rapid flow rate mode, minimizing certain risks associated with sub-arachnoid hemorrhages and sub-dural hematomas.

NPH is a form of chronic hydrocephalus that typically occurs in adults who are 60 years and older. It is characterized by a triad of clinical symptoms, including dementia, gait disturbance (i.e., difficulty walking), and urinary incontinence. As many as 10% of all patients with symptoms of dementia have NPH. While the symptoms associated with NPH can intensify over time if the condition is left untreated, if treated properly, the dementia associated with NPH can be reversed. Experts estimate that approximately 375,000 Americans have NPH. Based on current treatment statistics, we estimate that the market opportunity for shunt systems designed to treat NPH exceeds \$500 million.

Integra LifeSciences Holdings Corporation is a diversified medical technology company. Integra develops, manufactures, and markets medical devices used in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have research, manufacturing and distribution facilities located throughout the world. We have approximately 1,300 employees. Please visit our website at <http://www.Integra-LS.com>.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Integra NPH Valve. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, physicians' willingness to use the Integra NPH Valve may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2004 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACTS: Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

Maria Platsis
Senior Director of Corporate Development and
Investor Relations

(609) 936-2333
mplatsis@Integra-LS.com